BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 1422665)

  • 21. Thyroglobulin and 131I uptake of remaining tissue in patients with differentiated carcinoma after thyroidectomy.
    Moser E; Fritsch S; Braun S
    Nucl Med Commun; 1988 Apr; 9(4):262-6. PubMed ID: 3399222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The correlation of post-operative radioiodine uptake and Tc-99m pertechnetate thyroid scintigraphy and the result of thyroid remnant ablation.
    Thientunyakit T; Pusuwan P; Tuchinda P; Khiewvan B
    J Med Assoc Thai; 2013 Sep; 96(9):1199-207. PubMed ID: 24163997
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of low and high 131I doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on post-operative cervical uptake.
    Rosário PW; Reis JS; Barroso AL; Rezende LL; Padrão EL; Fagundes TA
    Nucl Med Commun; 2004 Nov; 25(11):1077-81. PubMed ID: 15577584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET.
    O'Connell ME; Flower MA; Hinton PJ; Harmer CL; McCready VR
    Radiother Oncol; 1993 Jul; 28(1):16-26. PubMed ID: 8234866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Commentary: Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma.
    Terris DJ
    Head Neck; 2010 Jun; 32(6):698-9. PubMed ID: 20187017
    [No Abstract]   [Full Text] [Related]  

  • 26. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.
    Pacini F; Molinaro E; Castagna MG; Lippi F; Ceccarelli C; Agate L; Elisei R; Pinchera A
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4063-8. PubMed ID: 12213846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
    Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Iodine-131 treatment of thyroid cancer: absorbed dose calculated from post-therapy scans.
    Koral KF; Adler RS; Carey JE; Beierwaltes WH
    J Nucl Med; 1986 Jul; 27(7):1207-11. PubMed ID: 3723194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Iodine scintigraphy of differentiated thyroid carcinoma].
    Nakata K; Tsukamoto E; Ito K; Kato C; Furudate M
    Rinsho Hoshasen; 1988 May; 33(5):589-90. PubMed ID: 3047462
    [No Abstract]   [Full Text] [Related]  

  • 30. Feasibility of low doses of I-131 for thyroid ablation in postsurgical patients with thyroid carcinoma.
    Siddiqui AR; Edmondson J; Wellman HN; Hamaker RC; Lingeman RE; Park HM; Johnston CC
    Clin Nucl Med; 1981 Apr; 6(4):158-61. PubMed ID: 7214770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma.
    Leger FA; Izembart M; Dagousset F; Barritault L; Baillet G; Chevalier A; Clerc J
    Eur J Nucl Med; 1998 Mar; 25(3):242-6. PubMed ID: 9580856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
    Cholewinski SP; Yoo KS; Klieger PS; O'Mara RE
    J Nucl Med; 2000 Jul; 41(7):1198-202. PubMed ID: 10914909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective.
    Higuchi T; Achmad A; Binh DD; Bhattarai A; Tsushima Y
    Endocr J; 2018 Mar; 65(3):345-357. PubMed ID: 29343651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Carcinoma of the thyroid in childhood].
    Sgro M; Spreafico GL; Colombo L; Musazzi R
    Minerva Chir; 1979 Jan 15-31; 34(1-2):63-72. PubMed ID: 481764
    [No Abstract]   [Full Text] [Related]  

  • 35. Local reactions to radioiodine in the treatment of thyroid cancer.
    Burmeister LA; du Cret RP; Mariash CN
    Am J Med; 1991 Feb; 90(2):217-22. PubMed ID: 1996591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Long-term course in differentiated thyroid gland carcinoma].
    Rösler H; Birrer A; Lüscher D; Kinser J
    Schweiz Med Wochenschr; 1992 Nov; 122(48):1843-57. PubMed ID: 1462145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of thyroid carcinoma imaging after therapeutic doses of radioiodine.
    Balachandran S; Sayle BA
    Clin Nucl Med; 1981 Apr; 6(4):162-7. PubMed ID: 7214771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effectiveness of high-dosage radioiodine therapy in the elimination of remnant tissue following total thyroidectomy].
    Schümichen C; Bulczak-Schmidt M; Blattmann H; Pauli-Harnasch C
    Nuklearmedizin; 1984 Oct; 23(5):265-9. PubMed ID: 6522276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pulmonary metastases from differentiated thyroid carcinoma demonstrable only by nuclear imaging.
    Bonte FJ; McConnell RW
    Radiology; 1973 Jun; 107(3):585-90. PubMed ID: 4702537
    [No Abstract]   [Full Text] [Related]  

  • 40. The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals.
    Morris LF; Waxman AD; Braunstein GD
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3507-11. PubMed ID: 11502771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.